Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites

NCT05745233 · clinicaltrials.gov ↗

NA

Phase

ENROLLING_BY_INVITATION

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Malignant Ascites

Interventions

DRUG: Nivolumab
DRUG: Pembrolizumab

Sponsor

China Medical University Hospital